-
Blood: two adjustment factors for vWF maturation and release: vesicles and BLOC-2
Time of Update: 2020-07-16
The !---- vascular hemophilia factor (vWF) is a necessary hemostatic protein that is synthesized in endothelial cells and stored in the Weibel-Palade small body (WPB) understanding the potential mech
-
Antibody-Drug Coupling Belantamab Mafodotin: Alarming Eye Toxicity
Time of Update: 2020-07-16
!---- briefing at a panel of FDA advisory panels on July 14, noted that GlaxoSmithKline's antibody-drug conjugate (ADC) Belantamab mafodotin is highly toxic to the eye, which is the main safety risk o
-
BMC Endocr Disord: Is there a link between thyroid disease and breast cancer?
Time of Update: 2020-07-16
The relationship between !---- breast cancer (BC) and thyroid disease (TD) remains controversial study to explore the possible coexistence of TD in newly diagnosed BC patients and their correlation w
-
JAMA Oncol: Detection of ctDNA and circulating tumor cells after new assisted chemotherapy predicts risk of recurrence of triple-negative breast cancer
Time of Update: 2020-07-16
!---- Currently, a large proportion of early-stage triple-negative breast cancer (TNBC) patients receive new complementary chemotherapy postoperative sequencing of circulating tumor DNA (ctDNA) combi
-
Roche CD20xCD3 Bispecific Antibody Mosunetuzumab Treatment Of Follicular Lymphoma, FDA Breakthrough Treatment Designation
Time of Update: 2020-07-16
Roche announced its CD20xCD3 bispecific antibody mosunetuzumab for recurrent or refractive (R/R) follicular lymphoma patients, who have previously received at least two systemic therapies, granted a b
-
JAMA Oncol: New Indiana University study, ctDNA and CTC combined to predict breast cancer recurrence more accurately
Time of Update: 2020-07-16
!----: Breast cancer is often referred to as the "pink killer", the incidence of female malignant tumors ranked first in China, the incidence of breast cancer is increasing year by year, more than 30
-
Mol Syst Biol: Drug screening combined with CRISPR technology to improve efficacy of anti-cancer drugs
Time of Update: 2020-07-16
!---- introduction: CRISPR comes from the immune system of microorganisms and is a game-changer in the field of biological science, a breakthrough technology that discovers, removes, and replaces spec
-
Targeting BCMA's ADC drug belantamab mafodotin, supported by an FDA advisory panel to treat patients with recurrent or refractive multiple myeloma
Time of Update: 2020-07-16
!---- The FDA advisory panel voted 12 to 0 tuesday in favor of targeting GlaxoSmithKline's antibody-drug conjugate (ADC) belantamab mafodotin to treat patients with recurrent or refractory multiple my
-
J Urol: Cardiovascular incidence of GnRH agonants VS antagonists in patients with advanced prostate cancer and cardiovascular disease
Time of Update: 2020-07-16
!---- androgen deprivation therapy may increase the risk of cardiovascular disease limited data suggest that GnRH (gonadotropin-releasing hormone) antagonist may reduce the risk of cardiovascular dis
-
Lancet oncol: Clinical activity of cabotinib for metastatic urethra cancer in platinum drug resistance
Time of Update: 2020-07-16
Cabotinib is a polykinase inhibitor of MET, VEGFR, AXL, and RET, and is equally effective in tumor immune microenvironments caused by the suppression of cell reduction from regulatory T cells and myel
-
Clin Genitourin Cancer: Relationship between prostate cancer morbidity and mortality and family history of prostate cancer
Time of Update: 2020-07-16
The purpose of this study is to determine the relationship between the family history of prostate cancer in first-degree relatives (FDrs) and the incidence and mortality of prostate cancer !---- rese
-
Cancer: Total metastasis and progression rate of prostate cancer in PLCO
Time of Update: 2020-07-16
the !---- prostate, lungs, colorectal, and ovarian (PLCO) cancer screening trials evaluated the effects of prostate-specific antigen screening and digital rectal examinations on prostate cancer mortal
-
Cancer: Effect of vascular endothelial growth factor in the treatment of metastatic thyroid cancer
Time of Update: 2020-07-16
!---- some multi-target tyrosine kinase inhibitors (TKIs) showed antitumor activity in patients with thyroid cancer resistant to radioactive iodine (RAI), in part because these TKIs inhibited the angi
-
Dev Cell: Cancer patients are saved by the latest study in the United States! A fatty acid can kill human cancer cells!
Time of Update: 2020-07-16
!---- Introduction: In medicine, cancer is a malignant tumor that originates in epithelial tissue, which is the most common type of malignant tumor what is commonly referred to as "cancer" is commonl
-
JGH Open: A Summary of Risk Factors for Hepatocellular Carcinoma
Time of Update: 2020-07-16
Liver cell carcinoma (HCC), !---- a primary liver cancer, is the third leading cause of cancer-related deaths worldwide in 2019, with approximately 841,000 new cases and 782,000 deaths each year the
-
Lymphoma Targets Immunotherapy! Roche CD79b target drug Polivy Japan applies for listing for diffuse large B-cell lymphoma (DLBCL)
Time of Update: 2020-07-15
, July 04, 2020 / Biogu BIOON/ -- Chugai, a Japanese pharmaceutical company controlled by Roche, has recently submitted a new drug application (NDA) to the Ministry of Health, Labour and Welfare (MH
-
the eLife virus uses immunoproteins to avoid the antiviral immune system!
Time of Update: 2020-07-15
, July 8, 2020 /PRNewswire/ -- Scientists have discovered a new antiviral defense system that can be used to treat many viral infections by discovering the glitot of the hepatitis C virus to evade
-
Cell apoptosis and checkpoint suppression! Asain Pharma has partnered with Mercado to develop MDM2-p53 inhibitor APG-115/Keytruda for the treatment of solid tumors!
Time of Update: 2020-07-15
, July 06, 2020 / Biovalley BIOON/ Ascent Pharma is a China-based, global-oriented research and development of original new drug products in the clinical stage, dedicated to the development of innov
-
TNBC's new drug! The first TROP-2 target antibody-drug conjugate Trodelvy III phase: significantly extended survival!
Time of Update: 2020-07-15
, July 07, 2020 /PRNewswire/ -- Biovalley BIOON/ --- Immunomedics is a pioneer in the next generation of antibody drug conjugate (ADC) technology, dedicated to helping cancer patients change their
-
Cervical cancer targeted therapy! Seattle Genetic Antibody Drug Coupling Tisotumab Vedotin Key PHASE II Study Positive Results!
Time of Update: 2020-07-15
, 2020 / PRNewswire / --Seattle Genetic seditography (Seattle Genetics) has announced positive top-line results from the Antibody Drug Couple (ADC) tisotumab vedotin for cervical cancer phase II i
